While Vor provided no details on the results, the company is now evaluating a global trial of the drug in the chronic immune ...

On August 13th, Remegen (688331.SH/09995.HK) announced that its global first-in-class BLyS (BAFF)/APRIL dual-target fusion protein drug, Telitacicept, met the primary endpoint in its Phase III ...

The China-based phase 3 trial of telitacicept in primary Sjögren's syndrome (pSS) met its primary endpoint, which focused on ...

Venus Williams is back on the professional tennis tour at age 45 and will be returning to the U.S. Open next week for her ...

Sjögren, who is currently head coach of Hammarby in Sweden’s top women’s flight, will join the club in January.

Jill M. Kramer, DDS, PhD, associate professor in the Department of Oral Biology at the University at Buffalo School of Dental ...

The questionable resume, and relaxed timeline of Sjögren's hiring leave more questions than answers around Stars' future ...